About this trial
Hepatic reperfusion during liver transplantation remains a critical phase associated with significant hemodynamic and systemic disturbances, despite advances in surgical and anesthetic management. This phase is characterized by the release of acidotic, hypothermic, and hyperkalemic blood containing metabolic byproducts and inflammatory mediators resulting from ischemia-reperfusion injury.
Clinically, reperfusion is associated with hemodynamic instability, including reductions in cardiac output and arterial pressure, as well as cardiac dysfunction and arrhythmias, often requiring pharmacologic support. These alterations may affect not only immediate intraoperative stability but also short- and long-term outcomes for both the patient and the graft.
The abrupt restoration of blood flow to the transplanted liver leads to the systemic release of accumulated metabolites, reactive oxygen species, and inflammatory mediators, contributing to a systemic inflammatory response that may impact distant organs, including the kidneys and heart.
Several revascularization strategies have been investigated to mitigate reperfusion-related injury: initial reperfusion via the portal vein, initial reperfusion through the hepatic artery, and simultaneous reperfusion through the portal vein and hepatic artery.
A less frequently used and insufficiently studied strategy, not routinely or systematically implemented, involves diverting the initial reperfusion blood from the graft to the surgical field, followed by the restoration of hepatic blood outflow to the systemic circulation.
This study hypothesizes that discarding the initial reperfusion blood via the infrahepatic vena cava will attenuate early hemodynamic, metabolic, and inflammatory changes and reduce postoperative complications compared to conventional reperfusion techniques.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults aged 18 years or older
Candidates for liver transplantation at Hospital das Clínicas, University of São Paulo Medical School (HCFMUSP)
Able to provide written informed consent
Disqualifiers
Inability to provide informed consent
Previous liver surgery
Fulminant hepatitis
Specific liver diseases associated with severe electrolyte disturbances
Trial design
Parallel
Treatments tested in this trial
Reperfusion Blood Discard
Procedure/SurgeryDiscarding of the initial 180 mL of reperfusion blood from the graft via the infrahepatic vena cava during liver transplantation prior to restoration of hepatic venous outflow to systemic circulation.
Standard Liver Transplantation
Procedure/SurgeryConventional liver transplantation without discarding the initial reperfusion blood.
Treatment groups
Trial outcomes
Primary outcomes
Peak alanine aminotransferase (ALT)
Peak serum ALT level (U/L) as a biomarker of early graft injury following liver transplantation.
Secondary outcomes
Arterial Pressure
Monitoring arterial pressure (systolic, diastolic e medium) Unit of Measure: mmHg.
Cardiac Rhythm
Cardiac rhythm monitoring with electrocardiography in ECG lead 2 and V5
Cardiac Output
Monitoring continuous cardiac output. Unit of Measure: L/min.
Arterial serum potassium levels
Perioperative changes in arterial potassium levels (Unit of measure: mEq/L).
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: